Many pharma AI programs fail to deliver returns because the business case is assembled *after* a technology decision has been made based on vendor pitches or technical interest. This backward approach ensures the financial justification is an afterthought, not a foundational element of the strategy.
The standard approach to AI efficiency is headcount reduction. A more profitable strategy is to model and execute the redeployment of employees' saved time into specific, value-creating activities. The financial model must explicitly choose and justify this path over simple cost savings.
To get CFO buy-in, don't just model the upside of AI investment. A more powerful approach is to include a baseline scenario showing the quantifiable business impact of delaying action. This frames the investment not just as an opportunity, but as a necessary defense against competitive disadvantage and market pressures like the patent cliff.
Firms often evaluate AI projects in isolation, leading to a portfolio of disconnected pilots. A rigorous financial model reveals how the *order* of implementation matters. An initiative that builds data infrastructure first can make a subsequent project three times more profitable than if it were implemented standalone.
Teams often build financial models to confirm their enthusiasm for a particular AI initiative. However, the model's greatest value comes from rigorously challenging these assumptions. Often, the most hyped projects are revealed to have a fraction of the financial impact of less visible but more strategic alternatives.
A CFO doesn't care that AI can summarize literature faster. They care that faster synthesis shortens publication times, accelerates HCP uptake, and impacts sales by a quantifiable amount. A credible financial case must map the entire chain of causality from an AI capability to a specific, revenue-driving business decision.